Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13182352 | 0.93 | MEN1 (0.53) | MAPTLMNAMEN1KMT2AKDM4E | |
| SCHEMBL2607490 | 0.88 | MEN1 (0.66) | MAPTLMNAMEN1KMT2AKDM4E | |
| SCHEMBL2607761 | 0.87 | MAPT (0.67) | MAPTLMNAMEN1KMT2AKDM4E | |
| SCHEMBL2607373 | 0.84 | MEN1 (0.56) | MAPTLMNAMEN1KMT2AKDM4E | |
| SCHEMBL2607751 | 0.83 | KDM4E (0.51) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2607588 | 0.83 | L3MBTL1 (0.56) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL2607586 | 0.83 | L3MBTL1 (0.63) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2607539 | 0.81 | MEN1 (0.78) | MAPTLMNAMEN1KMT2AKDM4E | |
| SCHEMBL2607552 | 0.77 | KDM4E (0.52) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2607591 | 0.76 | CTSD (0.59) | MAPTLMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-09 | — | — | US | disclosed |
| US-8969342-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | University of Georgia Foundation, Inc. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | MAPT 4129/4885LMNA 3978/4885MEN1 3561/4885 |
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | MAPT 4129/4885LMNA 3978/4885MEN1 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.